A patient with a stage IV mantle cell lymphoma (according to the REAL classification) was treated with high-dose chemotherapy and autologous bone marrow transplantation. One year later while on alpha-interferon immunotherapy she suffered from progressive loss of short-term memory and reported difficulties in recognizing objects. Magnetic resonance imaging (MRI) showed a vast ring-enhancing lesion of the left postcentral parietal area. Serial stereotactic biopsies disclosed progressive multifocal leukoencephalopathy without JC-virus in the cerebrospinal fluid. Therapy with subcutaneous interleukin-2 (IL-2) every other day and intrathecal cytarabine once a week was started. After 4 weeks the patient refused further treatment. Nevertheless her condition improved over the next 8 months and MRI scans showed a marked improvement in the lesions.
Immunodeficiency as induced by the human immunodeficiency virus (HIV), allogeneic bone marrow transplantation or therapy with purine analogues 1 forms a well known background for opportunistic infections like toxoplasmosis, 2 tuberculosis, 3 listeriosis 4 or progressive multifocal leukoencephalopathy (PML). 5 However the nature of the immunodeficiency may be important in allowing opportunistic infections. Thus, PML has been recognized with increasing frequency in HIV-infected patients 6 but there are also documented cases of PML in patients with lymphoma [7] [8] [9] or following bone marrow transplantation (BMT). 10, 11 We report the case of a patient with mantle cell lymphoma and non-HIV-associated PML 1 year after autologous BMT.
Case report
In May 1997, a 54-year-old female was hospitalized with complex neuropsychologic deficits including deterioration of short-term memory, apraxia and progressive fatigue. In June 1995, a mantle cell lymphoma (stage IVA with bone marrow involvement) was diagnosed. . This was tolerated without any major complications. She received 15 g intravenous immunoglobulin every other week until day 100 after ABMT. Starting on day 100 she received 3 ϫ 10 6 IU alphainterferon three times a week. In January 1997, the lymphocyte count was 1.0 ϫ 10 From May 1997, she suffered progressive loss of shortterm memory and reported difficulties in recognizing objects. A CT scan of the brain revealed a subcortical irregular non-enhancing lesion in the left postcentral parietal area without surrounding edema. Involvement of cortex, cerebellum and brain stem was excluded by MRI scans (Figure 1a ), which demonstrated a single ring-enhancing lesion. Positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) 12 was performed and demonstrated metabolic activity in the anterior margin of the lesion. Two days later serial biopsies were taken from the lesion in the left parietal lobe by stereotactic surgery. The tissue obtained showed severe multifocal demyelination ( Figure 2a ) and intact axonal structures in association with many macrophages and enlarged astrocytes. Additionally, predominantly perivascular infiltrations containing B-and T-lymphocytes, plasma cells with a few eosinophils were seen. Virus particles of the papova group were found in inclusion-bearing nuclei by immunohistochemical tech- The patient was treated with intrathecal cytarabine (40 mg) once a week for a total of three doses and subcutaneous IL-2 (9 ϫ 10 6 IU) every other day. After 4 weeks of treatment she refused further therapy. She was discharged from hospital and is followed in our out-patient facility with no specific therapy. MRI scans 3 months later demonstrated new lesions in the left periventricular white matter and the right parieto-occipital area (Figure 1b) . In April 1998 MRI scans were repeated: surprisingly, all prior known lesions were resolving (Figure 1c) . The lymphocyte count was 1. Meanwhile the patient learnt to handle the neurologic deficit and felt slightly better. She is currently in a rehabilitation center.
Discussion
We describe a case of PML in a patient with mantle-cell lymphoma after treatment with high-dose chemotherapy and autologous bone marrow transplantation. The polyomaviruses JC (JCV) and BK (BKV) are endemic in the human population. The seroconversion rate is 70% in young adults and up to 90% in the elderly. 13 Initially JCV was found exclusively in brain tissue of autopsy material affected with PML and not in patients without a history of PML. As shown by several groups 13, 14 JCV and BKV can establish a latent infection in the kidney, which is a known source for reactivation, and even in the central nervous system of nonimmunocompromised patients. By polymerase chain reaction, JCV was found in a high percentage of HIVinfected patients with PML and also in the brains of AIDS patients without clinically evident PML. 15 It can persist at this site without causing demyelinating disease. In cases of severe immunodeficiency induced by aggressive chemotherapy, after organ transplantation or by HIV infection JCV might be reactivated and lead to the development of PML. Recently, a so-called archetype of JCV and other strains, evolving by mutations within the promoterenhancer region, were distinguished. These variants resemble virus found in brain tissue affected by PML. 14, 16 Recently a review of molecular biology, pathogenesis and the clinical impact of PML was undertaken by Weber and Major. 17 It is reported that PCR has an overall sensitivity of 75% in the diagnosis of PML (for review see Ref. 17) . In AIDS patients with focal intracerebral lesions a clear cut morphological diagnosis could be established by stereotactic biopsy in 88%. 18 In our patient, PCR was negative but immunohistochemistry showed positivity for polyoma virus.
PML is usually a rapidly fatal disease with a survival of generally less than 6 months although longer clinical courses have been documented. 6 There is currently no effective therapy for PML. There are several reports of remission with various agents but none has proved reliable. 19 There is some experience with cytarabine given intrathecally. 20 O'Riordan et al 21 reported a case of a 51-year-old HIV-negative woman who was in complete remission from non-Hodgkin's lymphoma. PML was diagnosed and a rapid improvement occurred when intrathecal cytarabine was given. She was still in complete remission from both lymphoma and PML 20 months later. Berger et al 22 reported prolonged survival and partial recovery in two cases of AIDS-associated PML who have both survived for more than 30 months since the onset of symptoms. Brain tissue was characterized by an unusually prominent inflammatory response.
There are some contradictory reports on immunomodulation with interferon-alpha without evidence of definite efficacy in PML. Our patient received interferon-alpha maintenance therapy after autologous bone marrow transplantation when she developed neurological signs of PML. Although there are no data concerning immunomodulation with IL-2 in patients suffering from PML, we decided to start therapy with a dose known to have biological effects on the immune system. 23 Our patient had received three doses of intrathecal cytarabine and subcutaneous IL-2 without any benefit. Interestingly, a prominent atypical inflammatory reaction was found in association with areas of demyelination. This phenomenon has been observed in other cases of PML with a more benign course and was interpreted as a marker of preserved host resistance.
Clinical course may depend on immunological impairment. In our case the number of CD4 cells almost doubled within a year and might explain the prolonged survival. On the other hand, different genetic types of JCV may correlate with distinct clinical features in the PML they produce. In this case recovery might reflect the natural history of this type of PML.
In summary, we present a patient with prolonged survival (13 months) and stabilization of PML without specific treatment. As discussed by Berger et al 22 the unusually prominent inflammatory reaction seen may be a positive prognostic factor in patients with PML.
